Kalaris Therapeutics, Inc. (NASDAQ:KLRS) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$10 a share · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), William Blair Buyers: ADAR1 Capital Management; Coastlands Capital; Invus; RTW Investments; Samsara BioCapital; Woodline Partners LP Use of proceeds: Advance clinical development of TH103 for neovascular AMD, working capital and general corporate purposes | Dec 17, 2025 |